Aberdeen Group
MYGN icon

Aberdeen Group’s Myriad Genetics MYGN Stock Holding History

Aberdeen Group’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.47M Buy
1,308,933
+198,529
+18% +$901K 0.01% 645
2026
Q1 		$5M Buy
1,110,404
+224,603
+25% +$1.17M 0.01% 687
2025
Q4 		$5.45M Buy
885,801
+246,748
+39% +$1.79M 0.01% 692
2025
Q3 		$4.62M Buy
639,053
+409,460
+178% +$2.43M 0.01% 708
2025
Q2 		$1.22M Buy
+229,593
New +$1.36M ﹤0.01% 815

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Aberdeen Group's MYGN Position: Q2 2026 in Review

Aberdeen Group increased its Myriad Genetics (MYGN) stake by 18% in Q2 2026, buying an estimated $901K and bringing the position to 1,308,933 shares worth $7.47M. The position accounts for 0.01% of the portfolio, ranked #645.

Aberdeen Group first reported a position in MYGN in Q2 2025 and has held it in 5 quarters since. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Aberdeen Group held 1,308,933 shares of Myriad Genetics worth $7.47M as of Q2 2026.
  • Aberdeen Group bought 198,529 Myriad Genetics shares in Q2 2026, an estimated $901K.
  • Myriad Genetics made up 0.01% of Aberdeen Group's portfolio in Q2 2026, its #645 holding.
  • Aberdeen Group first reported a position in Myriad Genetics in Q2 2025 and has held it in 5 quarters since.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.